No Data
No Data
TD Cowen Maintains 10x Genomics(TXG.US) With Hold Rating, Cuts Target Price to $18
Leerink Partners Maintains 10x Genomics(TXG.US) With Buy Rating
Strategic Pricing and Market Expansion Drive 10x Genomics Buy Rating
TD Cowen Reaffirms Their Hold Rating on 10x Genomics (TXG)
Barclays Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $21
10x Genomics Delivers 'Single Cell for a Single Cent' With New Chromium Launches
No Data
No Data